LGALS3 and metabolic dysfunction-associated steatohepatitis: Pre-clinical outcomes of a galectin-3 inhibitor, the GR-MD-02, indicated its success in reversing NASH with cirrhosis, supporting clinical development trials in future that target advanced fibrosis/cirrhosis with NASH.